COVID-19 Vaccine Weekly Intel Report

Science, trial forecast, production and news analysis

April 23rd - Prepared for BIO, DCVMN, IFPMA
Over 9 billion doses could be produced this year
An analysis of forecasted production of vaccine candidates
Over 9 billion doses could be produced this year

An analysis of forecasted production of vaccine candidates split by candidate

- mRNA-1273 (Moderna)
- MVC-COV1901 (Medigen/Dynavax)
- NasoVAX (Altimmune)
- NVX-CoV2373 (Novavax)
- S-268019 (UMN Pharma)
- SCB-2019 (Clover/Dynavax)
- BNT162b2 (Pfizer/BioNTech)
- Ad26CovS1 (J&J)
- Ad5-nCoV (CanSino)
- AZD1222 (University of Oxford/AstraZeneca)
- BBIBP-CorV (Beijing/Sinopharm)
- CoronaVac (Sinovac)
- COVAXIN (Bharat/ICMR/NIV)
- CoviVac (Chumakov Federal Scientific Center)
- CVnCoV (Curevac)
- EpiVacCorona (VECTOR)
- GRAd-COV2 (Reithera/LeukoCare/Univercells)
- INO-4800 (Inovio Pharma)
- LUNAR-COV19 (Arcturus)
- COVAXIN (Bharat/ICMR/NIV)
- CoronaVac (Sinovac)
- CoviVac (Chumakov Federal Scientific Center)
- CVnCoV (Curevac)
- EpiVacCorona (VECTOR)
- GRAd-COV2 (Reithera/LeukoCare/Univercells)
- INO-4800 (Inovio Pharma)
- LUNAR-COV19 (Arcturus)

<table>
<thead>
<tr>
<th>Month</th>
<th>Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan-21</td>
<td>200,715,588</td>
</tr>
<tr>
<td>Feb-21</td>
<td>425,929,684</td>
</tr>
<tr>
<td>Mar-21</td>
<td>830,218,085</td>
</tr>
<tr>
<td>Apr-21</td>
<td>1,388,902,344</td>
</tr>
<tr>
<td>May-21</td>
<td>2,080,496,478</td>
</tr>
<tr>
<td>Jun-21</td>
<td>2,870,502,904</td>
</tr>
<tr>
<td>Jul-21</td>
<td>3,815,817,604</td>
</tr>
<tr>
<td>Aug-21</td>
<td>4,871,966,540</td>
</tr>
<tr>
<td>Sep-21</td>
<td>5,982,385,185</td>
</tr>
<tr>
<td>Oct-21</td>
<td>7,206,503,589</td>
</tr>
<tr>
<td>Nov-21</td>
<td>8,478,587,508</td>
</tr>
<tr>
<td>Dec-21</td>
<td>9,889,406,370</td>
</tr>
</tbody>
</table>
Vast majority of vaccine manufacturing deals have involved a collaboration

An analysis of the number of collaborations confirmed for vaccine manufacturing

Number of vaccine manufacturing deals: 275
Number of manufacturing deals that include some form of collaboration: 214
Copyright and disclaimer notice

**Copyright notice** All intellectual property rights in this publication and the information published herein are the exclusive property of Airfinity and may only be used under licence from Airfinity. Without limiting the foregoing, by accessing this publication you agree that you will not copy or reproduce or recirculate or distribute or use any part of its contents in any form or for any purpose whatsoever except under valid licence from Airfinity. Unauthorised distribution is strictly prohibited.

**Disclaimer** The data and other information published herein are provided on an "as is basis". Airfinity makes no warranties, express or implied, as to the accuracy, adequacy, timeliness, or completeness of the data or fitness for any particular purpose. Airfinity shall not be liable for any loss, claims or damage arising from any party's reliance on the data and disclaim any and all liability relating to or arising out of use of the data to the full extent permissible by law.

**Production forecast disclaimer** the research team collect information of deliveries and source of supply from publicly available sources and use this as a proxy to estimate how many doses have been exported from a certain manufacturing facility. Airfinity are not able to assess if stockpiles of vaccines have accrued at certain facilities. Production estimates are for production of the vaccine product and does not include the fill/finish of vaccines.
For more information

press@airfinity.com